>genosco

About genosco

This author has not yet filled in any details.
So far genosco has created 13 blog entries.

Yuhan signs $1.25 billion licensing deal with Janssen

Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.

By | November 6th, 2018|

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.

By | June 3rd, 2018|

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

By | June 3rd, 2018|

YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results

Genosco's pipeline GNS-1480 (YH25448) was presented at ASCO 2018. *ASCO stands for American Society of Clinical Oncology Annual Meeting.

By | June 3rd, 2018|

YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results

ASCO 2018 Poster Board: #356 • Abstract 9033; Byoung Chul Cho - First Author, Severence Hospital

By | May 16th, 2018|

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract

By | May 16th, 2018|

YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC

Genosco's pipeline GNS-1480 (YH25448) was presented at AACR Annual meeting 2018. *AACR stands for American Association for Cancer Research.

By | April 18th, 2018|

Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer

This article was published on Cancer Research - AACR Journals, doi: 10.1158/0008-5472.CAN-16-2432 in February 2017.

By | February 16th, 2017|

YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC

Genosco's pipeline GNS-1480 (Yuhan code: YH25448) was presented at the IASLC 17th World Conference on Lung Cancer in December 2016. ​ *IASLC stands for International Association for the Study of Lung Cancer.

By | December 7th, 2016|

Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

This article was published in The FEBS Journal, Volume 238, Issue 19, Pages 3613-3625 in October 2016.

By | October 1st, 2016|
Load More Posts